Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Shire
Shire
Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown
Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown
Fierce Pharma
Takeda
Japan
early retirement
Shire
M&A
Flag link:
Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale
Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale
Endpoints
Takeda
Shire
M&A
OTC
Flag link:
Takeda continues post-Shire selloff, inching closer to $10B goal
Takeda continues post-Shire selloff, inching closer to $10B goal
Endpoints
Takeda
Celltrion
M&A
Shire
South Korea
Flag link:
Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead
Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead
Endpoints
Takeda
IBD
SHP647
Shire
Flag link:
Takeda posts surprise profit a year after Shire mega-merger
Takeda posts surprise profit a year after Shire mega-merger
Pharmaforum
Japan
Takeda
Shire
M&A
earnings
Flag link:
Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray
Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray
Endpoints
Oyster Point Pharma
dry eye disease
OC-01
Allergan
Restasis
Shire
Xiidra
Flag link:
Former Shire execs set up shop to take a shot at 'under the radar' cancer target
Former Shire execs set up shop to take a shot at 'under the radar' cancer target
Endpoints
cancer
oncology
Shire
OncoOne
Flag link:
Takeda Pharmaceutical Raises Its Profit Outlook
Takeda Pharmaceutical Raises Its Profit Outlook
Motley Fool
Takeda
earnings
Shire
Flag link:
Takeda puts Shire biologics plant with 200 employees on the block
Takeda puts Shire biologics plant with 200 employees on the block
Fierce Pharma
Shire
Takeda
drug manufacturing
Flag link:
Takeda pares down products and jobs, revives Genzyme building plans
Takeda pares down products and jobs, revives Genzyme building plans
Bizjournals
Takeda
Shire
M&A
layoffs
Flag link:
Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m
Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m
Pharmaforum
Takeda
Shire
M&A
Acino
Middle East
Africa
Flag link:
Takeda breaks into top 20 largest pharmas with Shire merger
Takeda breaks into top 20 largest pharmas with Shire merger
Pharmaforum
Takeda
Shire
M&A
Flag link:
Takeda eyes emerging markets asset sale to trim its debt; report
Takeda eyes emerging markets asset sale to trim its debt; report
Pharmaforum
Takeda
Shire
M&A
emerging markets
Europe
Flag link:
Takeda staffers accuse drugmaker of favoring Shire employees during merger: report
Takeda staffers accuse drugmaker of favoring Shire employees during merger: report
Fierce Pharma
Korea
Shire
Takeda
employees
M&A
Flag link:
As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization
As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization
Endpoints
Takeda
Shire
R&D
restructuring
M&A
Flag link:
Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt
Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt
BioSpace
Takeda
Shire
M&A
Flag link:
In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
Endpoints
Mirum
IPOs
Shire
liver disease
Flag link:
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Fierce Pharma
Servier
oncology
Shire
M&A
Flag link:
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Fierce Pharma
Takeda
Shire
Novartis
M&A
Xiidra
dry eye disease
Flag link:
Novartis Considers Offer for Takeda Eye-Disease Assets
Novartis Considers Offer for Takeda Eye-Disease Assets
Bloomberg
Novartis
Takeda
Shire
eye disease
M&A
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »